PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 261.01 Billion KRW | 34.02% |
| 2022 | 194.75 Billion KRW | 26.4% |
| 2021 | 154.08 Billion KRW | 41.69% |
| 2020 | 108.74 Billion KRW | 29.66% |
| 2019 | 83.87 Billion KRW | 30.48% |
| 2018 | 64.28 Billion KRW | 18.01% |
| 2017 | 54.46 Billion KRW | 18.53% |
| 2016 | 45.95 Billion KRW | 22.69% |
| 2015 | 37.45 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 83.1 Billion KRW | 11.23% |
| 2024 Q1 | 74.71 Billion KRW | 6.79% |
| 2023 Q4 | 69.96 Billion KRW | 1.69% |
| 2023 Q2 | 66.79 Billion KRW | 20.48% |
| 2023 Q1 | 55.44 Billion KRW | 3.41% |
| 2023 Q3 | 68.8 Billion KRW | 3.01% |
| 2023 FY | 261.01 Billion KRW | 34.02% |
| 2022 Q1 | 45.26 Billion KRW | 7.66% |
| 2022 FY | 194.75 Billion KRW | 26.4% |
| 2022 Q4 | 53.61 Billion KRW | 16.11% |
| 2022 Q2 | 49.7 Billion KRW | 9.79% |
| 2022 Q3 | 46.17 Billion KRW | -7.09% |
| 2021 Q1 | 34.53 Billion KRW | 10.53% |
| 2021 Q2 | 38.79 Billion KRW | 12.32% |
| 2021 Q3 | 38.7 Billion KRW | -0.24% |
| 2021 Q4 | 42.04 Billion KRW | 8.64% |
| 2021 FY | 154.08 Billion KRW | 41.69% |
| 2020 Q2 | 27.69 Billion KRW | 33.96% |
| 2020 Q3 | 29.12 Billion KRW | 5.16% |
| 2020 Q4 | 31.24 Billion KRW | 7.28% |
| 2020 FY | 108.74 Billion KRW | 29.66% |
| 2020 Q1 | 20.67 Billion KRW | -13.07% |
| 2019 Q2 | 20.04 Billion KRW | -2.03% |
| 2019 FY | 83.87 Billion KRW | 30.48% |
| 2019 Q4 | 23.78 Billion KRW | 21.4% |
| 2019 Q3 | 19.59 Billion KRW | -2.25% |
| 2019 Q1 | 20.45 Billion KRW | 18.05% |
| 2018 FY | 64.28 Billion KRW | 18.01% |
| 2018 Q4 | 17.32 Billion KRW | 11.8% |
| 2018 Q3 | 15.49 Billion KRW | -8.61% |
| 2018 Q1 | 14.49 Billion KRW | -2.81% |
| 2018 Q2 | 16.95 Billion KRW | 17.0% |
| 2017 Q3 | 14.41 Billion KRW | 13.47% |
| 2017 Q2 | 12.7 Billion KRW | 2.05% |
| 2017 Q1 | 12.44 Billion KRW | 12.54% |
| 2017 FY | 54.46 Billion KRW | 18.53% |
| 2017 Q4 | 14.91 Billion KRW | 3.48% |
| 2016 Q4 | 11.05 Billion KRW | 0.2% |
| 2016 Q1 | 11.81 Billion KRW | 15.9% |
| 2016 FY | 45.95 Billion KRW | 22.69% |
| 2016 Q3 | 11.03 Billion KRW | -8.33% |
| 2016 Q2 | 12.03 Billion KRW | 1.87% |
| 2015 FY | 37.45 Billion KRW | 0.0% |
| 2015 Q4 | 10.19 Billion KRW | 4.56% |
| 2015 Q3 | 9.75 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -508.409% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -2622.992% |
| BINEX Co., Ltd. | 154.82 Billion KRW | -68.585% |
| Bioneer Corporation | 263.23 Billion KRW | 0.846% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -3915.398% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | -280.244% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -5250.049% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -6112.145% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 72.639% |
| Medy-Tox Inc. | 221.12 Billion KRW | -18.04% |
| Peptron, Inc. | 3.34 Billion KRW | -7710.27% |
| Amicogen, Inc. | 159.9 Billion KRW | -63.229% |
| Genexine, Inc. | 4.42 Billion KRW | -5796.384% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | -385.61% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -664.405% |
| ALTEOGEN Inc. | 96.52 Billion KRW | -170.413% |
| SillaJen, Inc. | 3.93 Billion KRW | -6525.384% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | -344.531% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -1429.575% |
| Genomictree Inc. | 3.41 Billion KRW | -7536.343% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -1297.496% |
| EASY BIO,Inc. | 165.38 Billion KRW | -57.82% |
| GI Innovation, Inc. | 5.31 Billion KRW | -4807.281% |